{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:52:51Z","timestamp":1791550371486,"version":"4.3.4"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Jiangsu Hansoh Pharmaceutical Group Co., Ltd","award":["HSM-10296-C153"],"award-info":[{"award-number":["HSM-10296-C153"]}]},{"name":"Jiangsu Hansoh Pharmaceutical Group Co., Ltd","award":["HSM-10296-C206"],"award-info":[{"award-number":["HSM-10296-C206"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2024YFA1210100"],"award-info":[{"award-number":["2024YFA1210100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Major Project on Noncommunicable Chronic Diseases","award":["2024ZD0530900"],"award-info":[{"award-number":["2024ZD0530900"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The benefits of offering first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for treatment-naive EGFR-mutant non\u2013small-cell lung cancer patients (NSCLC) with brain metastases (BMs) are unknown. This trial aims to assess the feasibility, safety, and efficacy of icotinib plus aumolertinib in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The phase I\/II trial (ChiCTR2100044216) employed a 3\u2009+\u20093 dose-escalation and dose-expansion design targeting EGFR-mutant NSCLC patients with baseline measurable BMs. Primary endpoints were the recommended phase II dose (RP2D) and feasibility. Major secondary endpoints included median overall survival (OS), systemic and intracranial progression-free survival (PFS and iPFS), objective response rate (ORR and iORR), and safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-four eligible patients were evaluated with a median follow-up of 41.4 months. The RP2D was 125 mg icotinib 3 times daily plus 110 mg aumolertinib once daily. Median PFS was 21.1 months (95% CI 14.6-27.6 months) and median OS was 40.8 months (95% CI 29.1-52.5). ORR was 95.8% and the disease control rate (DCR) was 100%. Median iPFS was 22.5 months (95% CI 17.5-27.6 months) with iORR of 91.7% and intracranial DCR of 100%. For safety profile, grade \u22653 treatment-related adverse events (TRAEs) occurred in 37.5% of patients. The most common any-grade TRAEs were increases in alanine aminotransferase, aspartate aminotransferase, creatine kinase, and rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of aumolertinib and icotinib shows encouraging efficacy and a tolerable safety profile in patients with EGFR-mutant NSCLC and BMs, supporting its potential as a therapeutic option warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag036","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:40:42Z","timestamp":1771591242000},"page":"1491-1501","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of aumolertinib\/icotinib combination therapy for naive\n                    <i>EGFR<\/i>\n                    -mutant non\u2013small-cell lung cancer patients with brain metastases: A phase I\/II study"],"prefix":"10.1093","volume":"28","author":[{"given":"Min","family":"Yu","sequence":"first","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caini","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen , Shenzhen, Guangdong, People\u2019s Republic of China (C.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youling","family":"Gong","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Fan","sequence":"additional","affiliation":[{"name":", The People\u2019s Hospital of Leshan Department of Hematology and Oncology , Leshan, Sichuan, People\u2019s Republic of China (H.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Radiology, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Peng","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weigang","family":"Xiu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwen","family":"Zou","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Zhong","sequence":"additional","affiliation":[{"name":", Yibin Second People\u2019s Hospital Department of Oncology , Yibin, Sichuan, People\u2019s Republic of China (Liq.Z.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqiong","family":"Liu","sequence":"additional","affiliation":[{"name":", Hospital of Shimian County Department of Oncology , Yaan, Sichuan, People\u2019s Republic of China (T.L.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Wang","sequence":"additional","affiliation":[{"name":", Sichuan Science City Hospital Department of Thoracic Surgery and Lung Cancer Center , Mianyang, Sichuan, People\u2019s Republic of China (X.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3390-9697","authenticated-orcid":false,"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]},{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University , Chengdu, Sichuan,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2026060305373241300_noag036-B1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"2026060305373241300_noag036-B2","doi-asserted-by":"publisher","first-page":"7589","DOI":"10.3892\/ol.2017.7125","article-title":"Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors","volume":"14","author":"Taniguchi","year":"2017","journal-title":"Oncol Lett"},{"key":"2026060305373241300_noag036-B3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1748-717X-6-166","article-title":"Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation","volume":"6","author":"Arrieta","year":"2011","journal-title":"Radiat Oncol"},{"key":"2026060305373241300_noag036-B4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2213-2600(17)30262-X","article-title":"Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial","volume":"5","author":"Yang","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026060305373241300_noag036-B5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2026060305373241300_noag036-B6","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026060305373241300_noag036-B7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026060305373241300_noag036-B8","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"2026060305373241300_noag036-B9","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"2026060305373241300_noag036-B10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain metastases in EGFR- and ALK-positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026060305373241300_noag036-B11","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026060305373241300_noag036-B12","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors","volume":"21","author":"Ercan","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026060305373241300_noag036-B13","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1200\/JCO.2020.38.15_suppl.9507","article-title":"Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"38","author":"Rotow","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026060305373241300_noag036-B14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"2026060305373241300_noag036-B15","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.21037\/tlcr-21-79","article-title":"Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study","volume":"10","author":"Xu","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"2026060305373241300_noag036-B16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2019.05.032","article-title":"Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non\u2013small-cell lung cancer patients","volume":"117","author":"Yao","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026060305373241300_noag036-B17","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag036\/67077398\/noag036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/6\/1491\/67077398\/noag036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/6\/1491\/67077398\/noag036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:37:41Z","timestamp":1780479461000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/6\/1491\/8495127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag036","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,23]]}}}